XML 28 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Stockholders' Equity / (Deficit) - USD ($)
$ in Thousands
Total
Preferred Stock [Member]
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Treasury Stock
Treasury Stock
Balance (in shares) at Dec. 31, 2022   29,057,000 4,038,000       0  
Balance at Dec. 31, 2022 $ 36,239 $ 3 $ 1 $ 412,149 $ 0 $ (375,914) $ 0  
Shares issued under the Standby Equity Purchase Agreements (in shares)     379,000          
Shares issued under the Standby Equity Purchase Agreements 34,258   $ 0 34,258        
Disbursement of funds to Sorrento Amount (20,000)     (20,000)        
Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)             (1,716,000)  
Repurchase of Treasury Stock, Preferred Stock, and warrants (143,721) (3)   (53,196)     $ (90,522)  
Issuance of penny warrants 10,401     10,401        
Issuance of common stock in connection with Settlement Agreement, (in shares)     14,000          
Issuance of common stock in connection with Settlement Agreement 750     750        
Conversion of Convertible Debentures into common stock, shares     18,000          
Conversion of Convertible Debentures into common stock 7,735     7,735        
Retainer shares issued (in shares)     114,000          
Retainer shares issued 0   $ 0          
Issuance of common stock upon warrants exercise, shares     1,000          
Issuance of common stock upon warrants exercise 521     521        
Stock options exercised (in shares)     10,000          
Stock options exercised 614     614        
Stock-based compensation 14,596     14,596        
Net income (loss) (114,331)         (114,331)    
Placement Agent Shares and October 2024 Placement Agent Warrants 0              
Conversion of Tranche B Notes into common stock 0              
StockBlock Warrants issued in connection with the December 2024 RDO 0              
Other comprehensive income 0              
Stock-based compensation 14,596              
Balance at Dec. 31, 2023 $ (172,938) $ 0 $ 1 $ 407,828 0 (490,245) $ (90,522) $ (90,522)
Balance (in shares) at Dec. 31, 2023   29,057,000 4,574,000       (1,716,000)  
Balance, ( In shares) at Dec. 31, 2023               1,716,000
Stock options exercised (in shares) 46,000   1,000 46,000        
Net income (loss) $ (24,377)         (24,377)    
Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value 156     $ 156        
Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share     5,000          
Shares issued under Bought Deal Offering     168,000          
Shares issued under Bought Deal Offering 3,769     3,769        
Stock-based compensation 3,558     3,558        
Balance at Mar. 31, 2024 (189,786)   $ 1 415,357   (514,622)   $ (90,522)
Balance (in shares) at Mar. 31, 2024   29,057,000 4,748,000          
Balance, ( In shares) at Mar. 31, 2024               1,716,000
Balance (in shares) at Dec. 31, 2023   29,057,000 4,574,000       (1,716,000)  
Balance at Dec. 31, 2023 (172,938) $ 0 $ 1 407,828 0 (490,245) $ (90,522) $ (90,522)
Balance (in shares) at Dec. 31, 2023               1,716,000
Retainer shares issued (in shares)     286,000          
Retainer shares issued 0   $ 0          
Issuance of common stock upon warrants exercise, shares     321,000          
Issuance of common stock upon warrants exercise 2,311   $ 0 2,311        
Stock options exercised (in shares)     4,000          
Stock options exercised 227     227        
Stock-based compensation 15,690     15,690        
Net income (loss) (72,807)         (72,807)    
Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value 2,671     2,671        
Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share     81,000          
Shares issued under Bought Deal Offering     168,000          
Shares issued under Bought Deal Offering 3,769   $ 0 3,769        
Shares issued under Registered Direct Offering, shares     429,000          
Shares issued under Registered Direct Offering 5,919   $ 0 5,919        
Placement Agent Warrants issued in connection with Registered Direct Offering and Representative Warrants issued in connection with Bought Deal Offering 956     956        
Fee Warrant issued in connection with the Commitment Letter 310     310        
Repurchase of warrants (298)     (298)        
Common stock issuable under Sponsor Interest Purchase Agreement 345     345        
Placement Agent Shares and October 2024 Placement Agent Warrants, Shares     63,000          
Placement Agent Shares and October 2024 Placement Agent Warrants 3,792     3,792        
Conversion of Tranche B Notes into common stock, Shares     263,000          
Conversion of Tranche B Notes into common stock 9,256   $ 0 9,256        
Shares issued under December 2024 RDO, Shares     753,000          
Shares issued under December 2024 RDO, Value 328   $ 0 328        
StockBlock Warrants issued in connection with the December 2024 RDO 1,265     1,265        
Stock dividend declared, not yet distributed, Shares   5,000,000            
Stock dividend declared, not yet distributed   $ 1   (1)        
Shares issued under ESPP, shares     10,000          
Shares issued under ESPP 246     246        
Other comprehensive income 6,317       6,317      
Stock-based compensation 15,689              
Balance at Dec. 31, 2024 (192,641) $ 1 $ 1 454,614 6,317 (563,052) $ (90,522) $ (90,522)
Balance (in shares) at Dec. 31, 2024   34,057,000 6,952,000       (1,716,000)  
Balance, ( In shares) at Dec. 31, 2024               1,716,000
Net income (loss) (26,080)         (26,080)    
Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral 2,182     (5,353)       $ 7,535
Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral, Shares               (143,000)
Treasury Stock paid for Gloperba Ex-U.S. License 366     (808)       $ 1,174
Treasury Stock paid for Gloperba Ex-U.S. License, Shares               (22,000)
Treasury Stock transferred to Oramed for the Oramed Note maturity extension 1,375     (3,523)       $ 4,898
Treasury Stock transferred to Oramed for the Oramed Note maturity extension, Shares               (93,000)
Stock-based compensation 3,314     3,314        
Balance at Mar. 31, 2025 $ (211,484) $ 1 $ 1 $ 448,244 $ 6,317 $ (589,132)   $ (76,915)
Balance (in shares) at Mar. 31, 2025   34,057,000 6,952,000          
Balance, ( In shares) at Mar. 31, 2025               1,458,000